An SGLT2 inhibitor (empagliflozin) is started in a type 2 diabetic patient with CKD (eGFR 28 mL/min/1.73m²). Which specific beneficial renal mechanism justifies its use despite reduced glycosuric efficacy at low GFR?

• A Empagliflozin directly inhibits RAAS activation in the kidney
• B SGLT2 inhibition increases tubuloglomerular feedback by increasing NaCl delivery to macula densa, reducing hyperfiltration ✓
• C Empagliflozin reduces glomerular filtration pressure by afferent arteriolar dilation
• D Glycosuric effect persists below eGFR 30 mL/min via SGLT1 inhibition

Explanation

SGLT2 inhibitors reduce proximal tubular sodium-glucose reabsorption, increasing NaCl delivery to the macula densa (distal tubule). This restores tubuloglomerular feedback, causing afferent arteriolar constriction and reducing intraglomerular pressure (reducing hyperfiltration) — independent of glycemic lowering. This renoprotective mechanism is maintained even at low GFR (eGFR 20–45 mL/min), though glycosuric effect diminishes. Empagliflozin and dapagliflozin have demonstrated CKD progression reduction and are approved for CKD with albuminuria regardless of diabetes status.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.